The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity in vitro and in vivo

Glioblastomas (GBMs) are among the most malignant of all human tumors and have poor prognosis. The current standard of care (SOC) includes maximal surgical tumor resection followed by adjuvant temozolomide (TMZ) and concomitant radiotherapy (RT). However, even with this treatment, the 5-year surviva...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Fei, Zhang, Jinying, Liu, Hongyu, Wu, Liangliang, Jiang, Hongyu, Wu, Qiyan, Liu, Tianyi, Lou, Meiqing, Wu, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787502/
https://www.ncbi.nlm.nih.gov/pubmed/29416647
http://dx.doi.org/10.18632/oncotarget.23091

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787502/
https://www.ncbi.nlm.nih.gov/pubmed/29416647
http://dx.doi.org/10.18632/oncotarget.23091

Ejemplares similares